We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Celgene on Tuesday announced that the FDA granted priority review to a marketing application seeking approval of the JAK2 inhibitor fedratinib for the treatment of patients with myelofibrosis, setting a target action date of September 3.